Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of unusually large options trading activity on Thursday. Traders acquired 57,085 call options on the company. This is an increase of approximately 29% compared to the typical daily volume of 44,315 call options.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

NASDAQ:SLS traded down $0.39 during midday trading on Thursday, reaching $9.99. 5,660,522 shares of the stock traded hands, compared to its average volume of 7,890,419. The stock has a market capitalization of $2.02 billion, a P/E ratio of -47.67 and a beta of 2.56. SELLAS Life Sciences Group has a 12 month low of $1.39 and a 12 month high of $15.88. The company has a fifty day moving average of $12.31 and a 200 day moving average of $8.50.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Institutional Trading of SELLAS Life Sciences Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nykredit A S bought a new stake in SELLAS Life Sciences Group in the second quarter valued at $27,000. GAMMA Investing LLC increased its position in SELLAS Life Sciences Group by 293.2% during the 3rd quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after purchasing an additional 1,630 shares during the period. Sterling Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 900.8% in the 3rd quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock worth $82,000 after purchasing an additional 5,972 shares in the last quarter. City State Bank bought a new position in SELLAS Life Sciences Group in the 3rd quarter worth $100,000. Finally, California State Teachers Retirement System lifted its position in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after purchasing an additional 1,709 shares during the period. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.

SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.